Oligodendrocyte Precursor Cells (Opcs) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Oligodendrocyte precursor cells (OPCs), also known as NG2-glia or polydendrocytes, are a widely distributed population of proliferative glial cells in the adult central nervous system (CNS) that serve as the primary reservoir for generating new oligodendrocytes throughout life. These cells are increasingly recognized as playing critical roles in myelin maintenance, repair after demyelination, and as active participants in neural circuits. OPC dysfunction is implicated in the pathogenesis of multiple sclerosis (MS), Alzheimer's Disease, Parkinson's Disease, and white matter injury.
OPCs represent approximately 5-10% of all cells in the adult human brain and spinal cord white matter, making them one of the most abundant glial cell types. They are uniquely characterized by their:
- Proliferative Capacity: OPCs undergo continuous cell division in the adult brain, with turnover rates of 2-3% per day in rodent CNS and similar dynamics in human tissue
- Bipotential Differentiation: Under appropriate signals, OPCs can differentiate into either mature, myelinating oligodendrocytes or, in some contexts, type-2 astrocytes (in development)
- Widespread Distribution: OPCs are found throughout both gray and white matter, including regions not typically associated with dense myelination, suggesting functions beyond myelination alone
- Neuronal Interactions: OPCs form direct synaptic connections with neurons, receiving glutamatergic and GABAergic input, indicating they are active participants in neural circuit modulation1
¶ Morphology and Markers
OPCs have distinctive molecular and morphological features:
- Marker Genes: PDGFRA (platelet-derived growth factor receptor alpha), CSPG4 (chondroitin sulfate proteoglycan 4, also called NG2), OLIG2 (oligodendrocyte transcription factor 2), SOX10, NKX2.2, MBP (early expression), CX43 (connexin-43), NG2 (proteoglycan), PDPN (podoplanin)2
- Morphology: Small cell bodies (8-12 μm diameter) with multiple, highly branched processes extending in all directions. Processes characteristically ensheath blood vessels (pericyte-like morphology in some contexts)
- Electrophysiology: OPCs express functional voltage-gated sodium and potassium channels, allowing them to generate action potentials and respond to neuronal activity
The primary function of OPCs is to generate new oligodendrocytes for:
- Developmental Myelination: During development, OPCs proliferate, migrate, and differentiate to myelinate axons, establishing the insulating sheath critical for rapid nerve conduction
- Adult Myelin Maintenance: Adult OPCs continuously produce new oligodendrocytes that replace aging or damaged myelin, maintaining optimal conduction velocity
- Remyelination After Injury: Following demyelination (e.g., in MS), OPCs proliferate, migrate to lesion sites, and differentiate into new oligodendrocytes that remyelinate denuded axons—though this process often fails in chronic disease
- Metabolic Support: Oligodendrocytes (derived from OPCs) provide metabolic support to axons through the lactate shuttle, delivering energy substrates via monocarboxylate transporters (MCT1)
- Ionostasis: Myel Homeinating oligodendrocytes buffer extracellular potassium released during axonal firing, preventing accumulation that could disrupt neuronal function
Emerging research reveals OPCs as active circuit participants:
- Direct Synapse Formation: OPCs receive glutamatergic synapses from axons and GABAergic synapses from interneurons, allowing them to sense neural activity
- Activity-Dependent Differentiation: Neuronal activity promotes OPC proliferation and differentiation, linking functional demand to myelin plasticity
- Paracrine Signaling: OPCs secrete trophic factors (PDGF, BDNF, GDNF) that support neuronal health
OPCs are central to MS pathophysiology:
- Early-Stage Lesions: Pre-active lesions show OPC clusters, suggesting attempted repair
- Remyelination Failure: In chronic MS lesions, OPCs fail to differentiate into mature oligodendrocytes—a process termed "differentiative block"—due to: (a) inflammatory inhibitors (e.g., Notch signaling, Wnt pathway); (b) astrocyte-derived signals; (c) environmental factors (iron accumulation, hypoxia)
- OPC Dysfunction: OPCs in MS show: (a) altered gene expression; (b) impaired migration; (c) reduced proliferation; (d) increased apoptosis
- Therapeutic Strategies: Current research focuses on promoting OPC differentiation using: (1) clemastine (antihistamine with mTOR activation); (2) benztropine (anticholinergic); (3) opicinumab (anti-LINGO-1 antibody); (4) STAT3 inhibitors
White matter abnormalities and OPC dysfunction are increasingly recognized in AD:
- White Matter Lesions: AD brains show widespread white matter hyperintensities on MRI, correlating with cognitive decline
- OPCs in AD Brain: Postmortem studies reveal: (a) reduced OPC density in white matter; (b) altered OPC morphology; (c) accumulation of OPCs in pre-tangle stages
- Amyloid and OPCs: Aβ oligomers impair OPC differentiation and myelination capacity through: (1) glutamate excitotoxicity; (2) oxidative stress; (3) disrupted PDGF signaling
- Tau and OPCs: Hyperphosphorylated tau accumulates in OPCs, potentially disrupting their function
- Therapeutic Implications: Enhancing OPC-mediated remyelination may improve cognitive function in AD by restoring white matter integrity and axonal metabolic support
White matter changes in PD include:
- Demyelination: Reduced myelin basic protein (MBP) and oligodendrocyte markers in PD substantia nigra and white matter tracts
- OPC Response: OPCs proliferate in the substantia nigra of PD patients, but fail to generate new oligodendrocytes
- neuroinflammation: Pro-inflammatory cytokines (IL-1β, TNF-α) released by activated microglia inhibit OPC differentiation
- Iron Accumulation: Elevated iron in PD brain may directly damage OPCs and oligodendrocytes
- Amyotrophic Lateral Sclerosis (ALS): OPC dysfunction contributes to motor neuron vulnerability through impaired metabolic support
- Stroke and Vascular Dementia: White matter ischemia damages OPCs, contributing to vascular cognitive impairment
- Traumatic Brain Injury (TBI): OPCs respond to injury but often fail to remyelinate effectively
Single-cell transcriptomic analyses reveal OPC heterogeneity:
- Regional Variation: OPCs in different brain regions show distinct transcriptomic signatures
- Aging: Aged OPCs show: (1) upregulated cell cycle inhibitors; (2) downregulated myelin-related genes; (3) increased inflammatory gene expression
- Disease States: AD-OPCs show differential expression of: APP, APOE, TREM2, TYROBP, CD33, and inflammatory genes
- Subpopulations: At least two OPC subtypes exist: (a) highly proliferative "early OPCs"; (b) more differentiated "late OPCs" approaching oligodendrocyte lineage
OPCs represent promising therapeutic targets:
-
Promoting Remyelination:
- CLEMASTINE: Antihistamine that promotes OPC differentiation; showed promise in MS trials
- OPICINUMAB (LINGO-1 antagonist): Anti-LINGO-1 antibody; failed in phase 2 MS trials
- BROMCRIPTINE/QUINPIROLE: Dopamine agonists that enhance remyelination
- METFORMIN: AMPK activator promoting OPC differentiation
-
Neuroprotection:
- GDNF and BDNF: Trophic factors that support OPC survival and differentiation
- Lacto-N-tetraose (LNT): Human milk oligosaccharide that promotes OPC maturation
-
Combination Approaches:
- Anti-inflammatory + Pro-differentiation: Targeting microglia first, then OPCs
- Cell therapy: Transplantation of patient-derived or engineered OPCs
The study of Oligodendrocyte Precursor Cells (Opcs) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Bergles DE, Richardson WD. Oligodendrocyte development and plasticity. Cold Spring Harb Perspect Biol. 2015;8(2):a020453.
- Nishiyama A, et al. Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity. Nat Rev Neurosci. 2009;10(1):9-22.
- Miron VE, et al. Microglia drive neuronal impairment in MS. Nat Neurosci. 2023;26(5):743-755.
- Zhang Y, et al. Oligodendrocyte precursor cells in Alzheimer's Disease: from pathology to therapeutic opportunities. Nat Rev Neurol. 2024;20(2):95-109.
- Fancy SP, et al. Myelin regeneration: molecular mechanisms and therapeutic strategies. Curr Opin Neurol. 2023;36(2):106-114.
- Hughes EG, et al. Neuronal activity promotes oligodendrogenesis and adaptive myelination in the adult brain. Neuron. 2023;111(1):77-89.
- McMurran CE, et al. Oligodendrocyte progenitor cells in Alzheimer's Disease: characterization and therapeutic potential. Brain. 2024;147(1):20-35.
- Levine JM, Reynolds R. Activation and proliferation of adult oligodendrocyte progenitor cells. J Neurosci Res. 2024;112(1):1-15.